We reviewed longitudinal recruitment data to assess recruitment into head and neck cancer trials, and to identify factors that could influence this and affect their acceptability to patients. We retrieved data from the prospective computerised database (2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016) to measure acceptability to patients using the recruitment:screening ratio, and compared observational with interventional studies, single specialty (or site) with multispecialty (or site) studies, and step-up randomisation with non-inferiority randomisation designs. A total of 1283 patients were screened and 583 recruited. The recruitment:screening ratio for all the studies combined was 0.47 (486/1133). Studies that involved treatment by several specialties or at several sites had a significantly adverse impact on acceptability (p = 0.01).
Introduction
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Recruitment into head and neck clinical trials can be impeded by insufficient resources or logistical support, and poor acceptability to patients. Known barriers include patient preferences for the type of treatment, aversion to randomisation, lack of equipoise amongst clinicians, and the complexity of the trial design and the information provided. We have therefore reviewed longitudinal recruitment data from a head and neck clinical trials team (since its inception) at a district teaching hospital to assess recruitment into head and neck clinical trials, and to identify factors that influence this and indicate their acceptability to patients.
Patients and methods
We used the computerised prospective database of the head and neck team at the Bradford The acceptability of a study to patients (or relative success of recruitment into a clinical trial)
is measured by the recruitment:screening ratio. The complexity of a trial or the acceptability of a NIHR portfolio trial to patients is reflected by the recruitment:projected recruitment target ratio. We compared observational with interventional, single specialty (or site) with multispecialty (or site), and step-up randomisation with non-inferiority, trials. The objective of non-inferiority trials is to compare a new treatment with an active treatment to show that it is not clinically worse with regards to a specified endpoint. It is assumed that the comparator treatment has a significant clinical effect compared with placebo. We used the " t test to compare the mean of the ratios (GraphPad QuickCalcs 7, GraphPad Software Inc). Probabilities of less than 0.05 were considered significant.
Results
Sixteen observational and interventional studies were opened to recruitment by the head and neck multidisciplinary team at Bradford Teaching Hospitals during the study period ( Table 2 . The mean recruitment:screening and recruitment:target ratios were lower for observational studies than for interventional studies, but not significantly so (Table 3A and B). Comparison of the mean recruitment:screening ratios showed a significant preference for studies that involved a single specialty or site compared with those that involved several, but differences in the mean recruitment:target ratios were not significant (Table 4A and B). When randomised controlled trials were assessed separately, the mean recruitment:screening ratios were significantly lower in non-inferiority studies than in those that randomised patients to standard treatment, or to step-up or additional treatment groups, for example, LIHNCS and NIMRAD (Table 5) .
Discussion
To our knowledge, this study is one of the first to compare recruitment and screening data trials, the duration and frequency of travel that the protocols in both require (the nearest hyperbaric treatment centre is 60 miles away in Hull) will probably have made participation less attractive. Some clinicians and patients could also have formed personal views on the value of the treatment, which would challenge the concept of equipoise. 5, 6 The difficulties involved in recruiting patients when the intention is to de-escalate treatment or the trial is perceived to be of a non-inferiority design, were reflected in the lower recruitment:screening ratios, although the difference was not significant. The publication of outcomes of several previous studies such as PARSPORT 7 and PET-NECK 8 would reassure patients that governance in the design of NIHR portfolio trials is robust and safe, and would highlight the fact that quality of life is as important as cure. The involvement of a patient-led support group might encourage newly-diagnosed patients to take part, but this could add to the burden of a new diagnosis, and would need to be approached carefully and tactfully. On Ideally, from the perspective of a trials team, a strategically planned portfolio that allows several active studies or trials with different designs and target groups (for example, a combination of prevention or early detection, HPV and non-HPV cancers, carcinomas with unknown primaries, and survival and management of late toxicity) to run concurrently, would ensure that trials were available to more patients. This would reduce competition for a specific group, and the diversity of studies in the portfolio would ensure that the head and neck trials team had plenty to do, which is vital for successful recruitment.
Nationally, the relative strength of support for trials from surgical (Oral and Maxillofacial Surgery or Otorhinolaryngology) and oncological (Clinical Oncology or Medical Oncology) teams could be relevant to studies such as PET-NECK and DeESCALaTE, in which many patients would initially be referred to surgeons. This can also reflect local compared with national recruitment, so issues about the generalisability of the findings in this study must be taken into consideration.
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